These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7700043)

  • 21. Effect of interferon-gamma in dialysis fluid on peritoneal defence in rats.
    Calame W; Hendrickx RJ; Namavar F; Beelen RH
    Nephrol Dial Transplant; 1995; 10(7):1212-7. PubMed ID: 7478126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Host defense mechanisms in continuous ambulatory peritoneal dialysis.
    Rubin J; Lin LM; Lewis R; Cruse J; Bower JD
    Clin Nephrol; 1983 Sep; 20(3):140-4. PubMed ID: 6605227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages.
    Sach M; Loetscher P; Burger JA; Knopf HP; Schollmeyer P; Dobos GJ
    Adv Perit Dial; 1995; 11():19-23. PubMed ID: 8534702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal macrophage and lymphocyte cytoplasmic Ca2+: effects on peritoneal immune defense mechanisms and ultrafiltration capacity in continuous ambulatory peritoneal dialysis.
    Carozzi S; Nasini MG; Pietrucci A; Santoni O; Schelotto C; Caviglia PM
    Perit Dial Int; 1993; 13 Suppl 2():S286-90. PubMed ID: 8399590
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis.
    Hekking LH; Aalders MC; Van Gelderop E; Zweers MM; Struijk DG; Havenith CE; Beelen RH
    Adv Perit Dial; 1998; 14():14-8. PubMed ID: 10649683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific opsonic activity for staphylococci in peritoneal dialysis effluent during continuous ambulatory peritoneal dialysis.
    Nielsen H; Espersen F; Kharazmi A; Antonsen S; Ejlersen E; Joffe P; Pedersen FB
    Am J Kidney Dis; 1992 Oct; 20(4):372-5. PubMed ID: 1415206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of peritoneal dialysis solutions on peritoneal host defense.
    Mortier S; Lameire NH; De Vriese AS
    Perit Dial Int; 2004; 24(2):123-38. PubMed ID: 15119633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.
    Carozzi S; Nasini MG; Ravera M; Sanna A; Tirotta A; Lamperi S
    Adv Perit Dial; 1997; 13():7-12. PubMed ID: 9360642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host defence in CAPD treatment: the effect of the dialysate on cell function.
    van Bronswijk H; Verbrugh HA; Heezius EC; Verkooyen RP; van der Meulen J; Verhoef J
    Contrib Nephrol; 1990; 85():67-72. PubMed ID: 2078941
    [No Abstract]   [Full Text] [Related]  

  • 30. Peritoneal host defense mechanisms.
    Holmes CJ
    Perit Dial Int; 1996; 16 Suppl 1():S124-5. PubMed ID: 8728177
    [No Abstract]   [Full Text] [Related]  

  • 31. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients.
    Vlaanderen K; Bos HJ; de Fijter CW; Oe LP; van der Meulen J; Verbrugh HA; Beelen RH
    Nephron; 1991; 57(1):29-35. PubMed ID: 2046812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotyping by flow cytometry of peritoneal fluid of patients with peritonitis on continuous ambulatory peritoneal dialysis.
    Enríquez J; Klínger J; Arturo JA; Tobar C; Ceballos O
    Adv Perit Dial; 2002; 18():184-7. PubMed ID: 12402615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fas expression on peritoneal macrophages during continuous ambulatory peritoneal dialysis peritonitis.
    Chen CY; Wu CY; Tsai TC; Lin WT; Lee WJ; Su CC; Chen HC; Chiang HC
    Ren Fail; 2008; 30(3):297-301. PubMed ID: 18350449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis.
    Coban E; Ozdogan M; Tuncer M; Bozcuk H; Ersoy F
    J Nephrol; 2004; 17(3):427-30. PubMed ID: 15365965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The pathophysiology of fluid transport in continuous ambulatory peritoneal dialysis].
    Krediet RT; Struijk DG; Boeschoten EW; van der Reijden HJ; Kemperman FA; Arisz L
    Ned Tijdschr Geneeskd; 1989 Apr; 133(15):758-62. PubMed ID: 2654660
    [No Abstract]   [Full Text] [Related]  

  • 36. Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes.
    Liao CT; Andrews R; Wallace LE; Khan MW; Kift-Morgan A; Topley N; Fraser DJ; Taylor PR
    Kidney Int; 2017 May; 91(5):1088-1103. PubMed ID: 28065517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils.
    Haag-Weber M; Hörl WH
    Perit Dial Int; 1994; 14 Suppl 3():S33-8. PubMed ID: 7948273
    [No Abstract]   [Full Text] [Related]  

  • 38. Peritoneal membrane defence mechanism in CAPD.
    Lamperi S; Carozzi S; Nasini MG
    Contrib Nephrol; 1987; 57():69-78. PubMed ID: 3315441
    [No Abstract]   [Full Text] [Related]  

  • 39. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. 1.
    Lewis S; Holmes C
    Perit Dial Int; 1991; 11(1):14-21. PubMed ID: 2049417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation.
    Zemel D; Krediet RT; Koomen GC; Kortekaas WM; Geertzen HG; ten Berge RJ
    Nephrol Dial Transplant; 1994; 9(2):169-74. PubMed ID: 8190331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.